An Australian oncologist has questioned whether further trials of the antiangiogenesis therapy bevacizumab in metastatic cancers are justified in the absence of an overall survival benefit. Associate Professor Ian Haines of Monash University says the results from numerous trials of the anti-VEGF inhibitor in nine different cancer indications have only shown benefit in the ‘inferior’ ...
Time to stop using PFS outcomes for antiangiogenesis therapies: oncologist
By Michael Woodhead
28 Nov 2019